On Mar. 7, 2012, GE Healthcare announced an agreement to acquire Xcellerex,  a supplier of manufacturing technologies for the biopharmaceutical industry,  for an undisclosed amount.

, the acquisition will allow GE Healthcare to expand its  offering of products and services for the manufacture of biopharmaceutical  products such as recombinant proteins, antibodies, and vaccines. Xcellerex  develops and produces turn-key biomanufacturing systems and production-scale  bioreactors based around single-use components, including single-use bioreactor  systems that are complementary to GE Healthcare’s products and range of media  for cell culture. The companies believe that the strong strategic fit between  the two companies, combined with expanded capabilities in product development  and marketing, will offer significant customer benefits.

  Nigel Darby, vice-president of BioTechnologies, and chief technology officer  of GE Healthcare Life Sciences says in the release, “GE and Xcellerex share the  vision that an integrated approach, where we can help customers optimize every  stage of their manufacturing process, has the potential to increase production  flexibility and to deliver higher yields of finished product while reducing  time to market. With the global focus on spiraling health costs and the need  for sustainable healthcare, these are critical issues for the industry.”

  Guy Broadbent, president and CEO of Xcellerex, adds, “The integration of  Xcellerex’s products with GE Healthcare’s complementary capabilities in  upstream and downstream bioprocessing will help bring great benefits to our  customers.”

News

On Mar. 7, 2012, GE Healthcare announced an agreement to acquire Xcellerex, a supplier of manufacturing technologies for the biopharmaceutical industry, for an undisclosed amount.